Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-3641-2200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.38 billion
Profitability
Miscellaneous
Employees3,179
Next Earnings DateN/A
OptionableNot Optionable
Carl Zeiss Meditec (ETR:AFX) Frequently Asked Questions
What is Carl Zeiss Meditec's stock symbol?
Carl Zeiss Meditec trades on the ETR under the ticker symbol "AFX."
What price target have analysts set for AFX?
8 Wall Street analysts have issued twelve-month price objectives for Carl Zeiss Meditec's shares. Their forecasts range from €58.00 to €98.00. On average, they expect Carl Zeiss Meditec's share price to reach €84.06 in the next year. This suggests that the stock has a possible downside of 16.4%. View Analyst Price Targets for Carl Zeiss Meditec.
What is the consensus analysts' recommendation for Carl Zeiss Meditec?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carl Zeiss Meditec in the last year. There are currently 2 sell ratings, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Carl Zeiss Meditec.
Has Carl Zeiss Meditec been receiving favorable news coverage?
News stories about AFX stock have been trending positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Carl Zeiss Meditec earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Carl Zeiss Meditec.
Who are some of Carl Zeiss Meditec's key competitors?
Some companies that are related to Carl Zeiss Meditec include Siemens Healthineers (SHL), Sartorius (SRT), Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Senseonics (SENS), Senseonics (SENS), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG) and Oncosil Medical (OSL).
What other stocks do shareholders of Carl Zeiss Meditec own?
Who are Carl Zeiss Meditec's key executives?
Carl Zeiss Meditec's management team includes the folowing people:
- Dr. Ludwin Monz, Pres, CEO & Chairman of Management Board (Age 56)
- Mr. Justus Felix Wehmer, CFO & Member of the Management Board (Age 54)
- Mr. Jan Willem de Cler, Head of Surgical Ophthalmology & Member of Management Board
- Mr. Sebastian Frericks, Director of Investor Relations
- Mr. Martin Wiechmann, Head of the Planetarium Bus. Unit
What is Carl Zeiss Meditec's stock price today?
One share of AFX stock can currently be purchased for approximately €100.60.
How big of a company is Carl Zeiss Meditec?
What is Carl Zeiss Meditec's official website?
How can I contact Carl Zeiss Meditec?
Carl Zeiss Meditec's mailing address is Goeschwitzer Strasse 51-52, JENA, 07745, Germany. The company can be reached via phone at +49-3641-2200.
MarketBeat Community Rating for Carl Zeiss Meditec (ETR AFX)
MarketBeat's community ratings are surveys of what our community members think about Carl Zeiss Meditec and other stocks. Vote "Outperform" if you believe AFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFX will underperform the S&P 500 over the long term. You may vote once every thirty days.
